Semaglutide — the active ingredient in type 2 diabetes and weight-loss glucagon-like peptide-1 agonist ( GLP-1) medications Ozempic and Wegovy — may help lower dementia risk, a new study finds.

GLP-1 drugs like Ozempic have already become a game-changer for obesity and diabetes. But new research shows they may also ...

Memory loss might have met its match. A new study from Case Western Reserve School of Medicine suggests that GLP-1 weight loss drugs like Ozempic and Wegovy could lower your risk of developing ...

Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

In a nutshell People with type 2 diabetes taking semaglutide (Ozempic/Wegovy) showed up to 46% lower dementia risk compared to those on other diabetes medications The protective effects were ...

But up to half of all dementia cases might be preventable, and scientists have identified over a dozen modifiable risk factors that contribute to dementia risk, including obesity, type 2 diabetes ...

Ozempic Might Be a Dementia Buster, Too Ozempic Might Be a Dementia Buster, Too Research out today is the latest to suggest that semaglutide can significantly lower people’s risk of dementia.

People with type 2 diabetes are more likely to develop Alzheimer’s disease and other types of dementia than the general public. This may be because the diseases have similar risk factors, like ...

In a study funded by Novo-Nordisk, the Dutch pharmaceutical company that manufactures Ozempic, people treated with GLP-1 agonists ended up with an 11 percent decrease in risk for dementia.

A new study suggests that popular diabetes and weight-loss medications like Ozempic and Mounjaro may help protect against brain-related diseases such as dementia and stroke. Research followed ...

Some popular weight loss drugs — such as Ozempic, Mounjaro and Wegovy — may lower the risk of dementia and stroke for patients with Type 2 diabetes and obesity, new research suggests.